Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Completed · Phase 2

Conditions studied: Kidney Cancer, Metastatic Cancer

In brief

RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung. PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.

Key facts

Study ID
NCT00006483
Run by
Alliance for Clinical Trials in Oncology
People needed
27
Starts
2000-10-01
Expected to finish
2013-01-01
Last updated by the study team
2016-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.